November 16, 2023
Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients
- Grifols sCD38 is the industry’s first-ever soluble recombinant protein designed to overcome the interference that the cancer therapy daratumumab has on critical blood-transfusion tests
- The solution prevents daratumumab, which targets the CD38 protein on cancer cells, from binding to this specific protein on red blood cells and interfering in pre-transfusion compatibility testing
- Grifols sCD38 has received the CE mark and is another example of the company’s commitment to ensure the safety of the world’s blood supply
Barcelona, Spain, Nov. 16, 2023 – Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced the launch of its new Grifols sCD38 solution, the industry’s first-ever soluble recombinant protein designed to block anti-CD38 antibodies in multiple myeloma patients receiving daratumumab therapy, ensuring quick and accurate blood transfusion tests that are critical for proper treatment.
Daratumumab is a CD38-directed monoclonal antibody for treating multiple myeloma. However, during treatment the drug binds to the CD38 protein on red blood cells and can alter the results of critical blood pre-transfusion tests. This can delay lifesaving transfusions for these patients.
Grifols sCD38’s novel approach enables a more seamless screening, identification and crossmatching process when using Grifols’ DG Gel system for running pre-transfusion compatibility tests. When using this solution, laboratories have clearer clinical pictures with less effort compared with current alternative solutions.
“We are excited to announce the launch of Grifols sCD38, a first-of-its-kind solution that simplifies the process of blood transfusion testing with an easy, seamless methodology,” said Antonio Martínez, president of Grifols Diagnostic Business Unit. “Certification of Grifols sCD38 provides a reliable and efficient solution to ensure accurate and consistent results, demonstrating Grifols’ continued commitment to innovating blood transfusion safety.”
The Grifols sCD38 solution has received the CE mark and will be available in certain markets after completion of any additional registration and notification requirements.
About DG Gel System
The DG Gel system instruments and reagents use the DG Gel card technology to help labs streamline pretransfusion compatibility tests and tailor the extended phenotype profile for each patient's need. DG Gel system reagents include comprehensive DG Gel card profiles, reagent red blood cell options and complete liquid antisera.
To learn more, visit: https://www.diagnostic.grifols.com/en/dg-gel-system